Annual Drug Patent Expirations for GILOTRIF
Gilotrif is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are five patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for GILOTRIF.
This drug has one hundred and sixty-six patent family members in forty-six countries.
The generic ingredient in GILOTRIF is afatinib dimaleate. One supplier is listed for this compound. Additional details are available on the afatinib dimaleate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com